| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD8-HF255 | Human | FITC-Labeled Human CD38 Protein, Fc Tag |  |
|
|
| CD8-HF2H5 | Human | FITC-Labeled Human CD38 Protein, His Tag |  |
|
|
| MBC-K010 | Human | Human CD38-coupled Magnetic Beads |
|
||
| CD8-M5223 | Mouse | Mouse CD38 Protein, His Tag |  |
|
|
| CD8-C5223 | Cynomolgus | Cynomolgus CD38 Protein, His Tag |  |
|
|
| CD8-H5252 | Human | Human CD38 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| CD8-H5253 | Human | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD8-H5255 | Human | Human CD38 Protein, Fc Tag (MALS verified) |  |
|
|
| CD8-H82E7 | Human | Biotinylated Human CD38 Protein, Avitag™,His Tag |  |
|
|
| CD8-H5224 | Human | Human CD38 Protein, His Tag (MALS verified) |  |
|
|
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab | JNJ-54767414 | Approved | Janssen Global Services Llc | Darzalex, 兆珂, 兆珂速 | Mainland China | Multiple Myeloma | s:30:"Janssen-Cilag International Nv"; | 2015-11-16 | Lymphoma, B-Cell; Smoldering Multiple Myeloma; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Amyloidosis; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Large intestine neoplasm | Details |
| Daratumumab/Hyaluronidase-fihj | Approved | Janssen Global Services Llc | Darzalex Faspro | United States | Amyloidosis | s:19:"Janssen Biotech Inc"; | 2020-05-01 | Multiple Myeloma; Amyloidosis | Details | |
| Isatuximab | SAR-650984 | Approved | Immunogen Inc | Sarclisa | Japan | Multiple Myeloma | s:6:"Sanofi"; | 2020-03-02 | Bone Marrow Neoplasms; Carcinoma, Transitional Cell; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Hemolytic, Autoimmune; Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 89Zr-DFO-daratumumab | Memorial Sloan Kettering Cancer Center | Details | |||
| STI-6129 | STI-6129 | Phase 1 Clinical | Sorrento Therapeutics | Immunoglobulin Light-chain Amyloidosis | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity, Sorrento Therapeutics | Multiple Myeloma | Details | |
| CART-38 | CART-38 | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia, Myeloid, Acute | Details |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG301; SG-301 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma | Details |
| GBR-1342 | GBR-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| LQ-032 | LQ-032; LQ032 | Details | |||
| CID-103 | CID-103; TSK011010 | Phase 1 Clinical | Tusk Therapeutics Ltd | Hematologic Neoplasms; Multiple Myeloma | Details |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| AMG-424 | AMG-424 | Phase 1 Clinical | Amgen Inc, Xencor | Multiple Myeloma | Details |
| TAK-573 | TAK-573; TEV-48573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Multiple Myeloma; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| TAK-079 | TAK-079 | Phase 2 Clinical | Takeda | Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| MOR-202 | TJ-202; MOR-202; MOR-03087 | Phase 3 Clinical | Morphosys Ag | Multiple Myeloma; Glomerulonephritis, Membranous; Glomerulonephritis | Details |
| TAK-169 | TAK-169 | Molecular Templates | Details |
This web search service is supported by Google Inc.
A-Z